These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19245127)

  • 1. Blood product support of coagulation.
    Moormeier J
    Mo Med; 2009; 106(1):65-8. PubMed ID: 19245127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric hemostasis and use of plasma components.
    Goldenberg NA; Manco-Johnson MJ
    Best Pract Res Clin Haematol; 2006; 19(1):143-55. PubMed ID: 16377547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit.
    Motta M; Del Vecchio A; Radicioni M
    J Matern Fetal Neonatal Med; 2011 Oct; 24 Suppl 1():129-31. PubMed ID: 21942611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Required laboratory examination and blood transfusion therapy in massive hemorrhage during surgery].
    Yamamoto K
    Rinsho Byori; 2011 Jul; 59(7):678-83. PubMed ID: 21874794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelets, frozen plasma, and cryoprecipitate: what is the clinical evidence for their use in the neonatal intensive care unit?
    Poterjoy BS; Josephson CD
    Semin Perinatol; 2009 Feb; 33(1):66-74. PubMed ID: 19167583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical evaluation of cryoprecipitate for replacement of fibrinogen.
    Sørensen B; Bevan D
    Br J Haematol; 2010 Jun; 149(6):834-43. PubMed ID: 20456356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryoprecipitate transfusion in bleeding patients.
    Nascimento B; Levy JH; Tien H; Da Luz LT
    CJEM; 2020 Sep; 22(S2):S4-S11. PubMed ID: 33084562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and plasma products in the treatment of massive haemorrhage.
    Erber WN; Perry DJ
    Best Pract Res Clin Haematol; 2006; 19(1):97-112. PubMed ID: 16377544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
    Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
    Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a rationale use of frozen plasma for the treatment and prevention of bleeding.
    Tinmouth A
    Transfus Apher Sci; 2012 Jun; 46(3):293-8. PubMed ID: 22521566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate.
    Elliott BM; Aledort LM
    Expert Rev Hematol; 2013 Jun; 6(3):277-86. PubMed ID: 23782082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.
    Levy JH; Welsby I; Goodnough LT
    Transfusion; 2014 May; 54(5):1389-405; quiz 1388. PubMed ID: 24117955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of RiaSTAP after rapid reconstitution.
    Karri JV; Cardenas JC; Johansson PI; Matijevic N; Cotton BA; Wade CE; Holcomb JB
    J Surg Res; 2014 Aug; 190(2):655-61. PubMed ID: 24602482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on transfusion medicine.
    Shander A; Goodnough LT
    Pharmacotherapy; 2007 Sep; 27(9 Pt 2):57S-68S. PubMed ID: 17723109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryoprecipitate: the current state of knowledge.
    Callum JL; Karkouti K; Lin Y
    Transfus Med Rev; 2009 Jul; 23(3):177-88. PubMed ID: 19539873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII, factor IX and fibrinogen content in cryoprecipitate, fresh plasma and cryoprecipitate-removed plasma.
    Bejrachandra S; Chandanayingyong D; Visudhiphan S; Tumliang S; Kaewkamol K; Siribunrit U
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():162-4. PubMed ID: 7886562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The blood bank physician as a hemostasis consultant.
    Sweeney JD
    Transfus Apher Sci; 2008 Oct; 39(2):145-50. PubMed ID: 18760674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of blood components in cancer patients with bleeding.
    Bodensteiner DC; Tilzer LL; Adams ME; Bayer WL
    Hematol Oncol Clin North Am; 1992 Dec; 6(6):1375-92. PubMed ID: 1452518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice.
    Eltringham-Smith LJ; Lei X; Reheman A; Lambourne MD; Pryzdial EL; Ni H; Sheffield WP
    Transfusion; 2015 May; 55(5):1040-50. PubMed ID: 25403994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryoprecipitate. Patterns of use.
    Pantanowitz L; Kruskall MS; Uhl L
    Am J Clin Pathol; 2003 Jun; 119(6):874-81. PubMed ID: 12817436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.